From: Molecular signature of response to preoperative radiotherapy in locally advanced breast cancer
Variable | Reference vs. level | Hazard Ratio | (95% CI) | p-value |
---|---|---|---|---|
MAP3K4 level | (low vs. high) | 2.54 | (1.42, 4.55) | 0.002* |
ER/PR status | (ER+/PR+ vs. ER-/PR+ or ER+/PR-, ER-/PR-) | 1.20 | (0.94, 1.52) | 0.146 |
Age | (under 40 vs. 40–55, 56–70, over 70) | 0.81 | (0.53, 1.24) | 0.332 |
Menopause | (pre-menopausal vs. postmenopausal) | 1.19 | (0.58, 2.42) | 0.639 |
T-stage | (T1 vs. T2, T3, T4) | 1.08 | (0.75, 1.55) | 0.697 |